Profil bibliographique

W. Victoria Lai

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

54Publications signalées

2573Citations signalées

1Affiliations récentes

Les institutions déclarées

AstraZeneca (United States)

Les domaines associés

Lung Cancer Research StudiesLung Cancer Treatments and MutationsNeuroendocrine Tumor Research AdvancesCancer Immunotherapy and BiomarkersCancer therapeutics and mechanisms

Les publications récentes

2025 conference-abstract OpenAlex

Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).

David A. Barbie, Mingchao Xie, Maria A.S. Broggi, Ying Cheng et autres

us, jp, cn, kr, es, de, tr, ca, nl (code pays fourni par la source)

3 citations Journal of Clinical Oncology

Accès ouvert 2024 other OpenAlex

Data from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 other OpenAlex

Data from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Table 2 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Table 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Table 4 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Table 2 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Table 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplemental Table 3 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Table 4 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.